



“What Cures Within Reach does is absolutely magical. They have built an unmatched ecosystem and process to activate researchers and turn repurposing ideas into clinical success.”

2025 ANNUAL REPORT



Cures Within Reach finds and funds clinical repurposing trials: testing approved therapies to fast-track safe and effective treatments for unsolved diseases.

Our patient-first approach focuses on generating early clinical data to de-risk and catalyze follow-on funding by others for larger, confirmatory trials, building the clinical evidence required for regulatory approval or off-label use.

2025 Achievements

- **\$17 million raised** in catalytic, follow-on funding for our funded research
- **28 new publications or presentations** on our funded research
- **16 trials started** with our funding in immune disorders, infectious diseases, maternal health, neurology, oncology and more
- **12 trials completed** in infectious diseases, neurology, oncology and more
- **16 trials selected** and already underway or starting soon, in infectious diseases, maternal health, neurology, oncology and more
- **50 ongoing** clinical trials in **33 diseases** at **40 institutions** in **12 countries** at year-end

Celebrating Our 20th Year Impacting Patients with Unsolved Diseases

In October 2025, we celebrated our **20th anniversary**. Since 2005, we have funded 162 clinical trials in 94 different diseases at over 100 research institutions around the globe. Our successful treatment options for patients are growing, due to publications, presentations and the follow-on clinical evidence needed for broad use by patients anywhere.

What's next? With our customizable, flexible approach, we continue to solve emerging challenges and fill gaps, from AI validation to women's health and beyond.

Together We're Making Real Patient Impact

94



Diseases
Researched

162



Trials
Funded

102



Institutions
Funded

25



Success
Stories

\$145 million



Follow-On Raised
from Trials

To Our Stakeholders:

From all of us at Cures Within Reach, it is my pleasure to share this summary of 2025. Our team's passion hasn't wavered, and we are truly energized by your continued commitment to our mission: rapidly impacting patients with unsolved diseases through the testing of already approved therapies for new uses. We look forward to helping even more patients in 2026.

Please help us spread the word to impact more patients and more unsolved diseases by sharing this Annual Report and connecting us to funders and other partners in your network.

2025 Highlights:

- *Celebrated our 20th anniversary in October: honoring our past and looking to the future!*
- *Led the world's first Request for Proposals (RFP) of investigator-initiated clinical trials to validate AI predictions*
- *A record 146 volunteer Grant Reviewers helped our team review a record number of submissions*
- *A funding rate of 16% – quite strong, considering the medical research funding environment throughout 2025 and the significant increase in submitted requests*
- *\$17 million raised in catalytic, follow-on funding for our funded research*
- *Grew our portfolio of ongoing trials with our funding to a record 50 at year-end*

Our newest effort, funding clinical repurposing trials to validate AI-driven drug – disease matches had exciting progress, as Lyda Hill Philanthropies joined our lead funding partner Chan Zuckerberg Initiative, expanding our future impact. Final selections are imminent and will be shared within a few months. Most of these AI Validation trials will include funding for community engagement alongside the clinical trials.

We are grateful for the many physician scientists and researchers who share their repurposing ideas with us and move this work forward, the patients who participate in these clinical trials and our funding partners, community members and stakeholders. While this Annual Report features a few of our partners, we are incredibly grateful for all who contributed to our successful 2025.

Together we can improve the quality and length of life for patients faster through repurposing. They are counting on us.



Barbara Goodman
President & CEO



Cures Within Reach **tests approved therapies for unsolved diseases** by leveraging the speed, safety and cost-effectiveness of repurposing: driving more treatments to more patients more quickly.

We find and fund proof-of-concept clinical trials of drugs, devices and other treatments that, once successful, **de-risk and catalyze follow-on funding** for the larger, confirmatory trials, **building the clinical evidence** required for regulatory approval or to support off-label use by patients everywhere.

OUR IMPACT

Creating Patient Impact: Staying Focused on “Why”

Cures Within Reach and our funding partners are passionate about impacting patients with unsolved diseases by developing new treatments using already approved therapies, known as repurposing. As a disease-agnostic, geography-agnostic, risk-mitigating catalyzer, our current portfolio of ongoing trials with our funding covers a range of disease areas:

34% rare diseases	96% clinical, 4% pre-clinical
38% oncology	73% adult, 15% pediatric, 12% combination
24% neurology <i>(neurodegenerative, mental health, pain)</i>	72% US, 28% outside of US
12% infectious diseases	76% drug, 24% device/other
26% other	57% primary funder, 43% supplemental funder

as of 12.31.2025

We are grateful for the support of our donors, sponsors, funding partners, funded researchers/institutions, volunteer grant reviewers and patients in making these exciting clinical trials possible.

16 New Clinical Trials Selected for Funding

During 2025, we released 4 funding opportunity Request for Proposals (RFPs): Low/Low-Middle Income Country-based (LMIC) trials, Chicago-based trials, Meniere's disease and related disorders and AI Validation. In addition to the 16 new clinical trials selected (6 already underway), these RFPs resulted in:

- A **16% average funding rate**
- A record **169 Letters of Intent submitted**
- A record **146 volunteer Grant Review Committee members** supported our two-stage selection process

While 2025 was a challenging medical research funding environment in the US and beyond, it is clear that our funding of proof-of-concept clinical repurposing trials is more critical than ever. We can't stop building our pipeline. We remain optimistic that the catalytic, follow-on funding needed from government, philanthropy and industry will flow to build the clinical evidence needed for broad patient use.

Measuring Our Success

Our funded research moved forward through follow-on funding, publications of trial results and presentations at conferences, led by researchers as well as by commercial entities.

Clinical Trials With Early Positive Evidence

Clinical Trials with Early Positive Evidence:

Symptoms improved and/or early positive evidence in chronic pelvic pain, epilepsy, a rare immune disorder plus publications and/or presentations in several inner ear issues and PTSD.

Follow-On Funding for Follow-On Clinical Trials

Follow-On Funding:

Our past research saw **\$17 million in catalytic, follow-on funding raised** in a range of diseases and for many PIs, including in traumatic brain injury, pancreatic and other cancers, neurological diseases, rare diseases and inner ear diseases.

Clinical Results Impacting Patients Broadly


Clinical Results Impacting Patients Everywhere:

Whether from publications, presentations or further reimbursement, patients are accessing these treatment options in neurological diseases, prostate cancer and infectious diseases.

FUNDING AT THE KEY MOMENT

What we solve: **more viable treatment options for patients in need**

We provide **seed funds to de-risk and unlock a catalytic effect**, building the **clinical evidence required** for regulatory approval or off-label use by patients everywhere



Known as 'medical repurposing' by researchers, clinicians, patients and nonprofits, it is called life cycle management, indication expansion or label extension by the pharmaceutical industry.

DONOR-ADVISED IMPACT PHILANTHROPY


Join us! Spread the word to help bring treatment options to the millions who suffer with unsolved diseases

Philanthropy Focused on Speed-to-Impact

Together with our donor partners, we are supporting researchers with clinical repurposing ideas to quickly reach patients everywhere, de-risking new treatment options for patients.

- Donor partners choose their desired level of engagement in the design, search and selection process – our experienced team customizes the approach with you
- Grants starting at \$75,000 and up to \$250,000 or more can support a small, proof-of-concept human clinical trial or an expansion of an ongoing trial

Examples of Donor Partnerships:

Donor	Goal	Involvement	2025 Results
The Searle Funds at The Chicago Community Trust	Build the Chicago pipeline, impacting both researchers and patients	High level RFP guidance only	5 trials selected in 2025 plus more in 2026
Becky and Lester Knight	Build broad pipeline for Meniere's disease and related disorders	Very involved throughout our 2-stage selection process	Portfolio of 11 ongoing or completed trials plus 2 starting in 2026
Coefficient Giving	Tackle high disease burden in LMICs with readily available generics	Involved in up-front RFP design only	13 LMIC-based ongoing trials, 4 more starting in 2026 plus up to 9 to be selected in 2026
Chan Zuckerberg Initiative 	Validate AI-predicted matches in clinical trials while bridging AI model – PI connections	Involved in RFP design; helped connect patient/disease orgs	World's first AI Validation RFP for repurposing; selections made 1Q2026

Our 20-year successful track record in repurposing is complementary to lengthy *de novo* therapy research and has the potential to significantly reduce the time needed to reach as many patients as possible.

Our Value Proposition:

- An expert team providing bespoke services designed to meet your needs
- Technical expertise in finding, selecting, de-risking and managing our funded clinical trials
- Access to our vast global research network
- An efficient, proven RFP process, including volunteer, external Grant Review Committee members (representing research, industry, clinicians, nonprofits, philanthropy, government and the patient/community voice) that support trial selection and strengthen trial protocols
- Project and financial progress reports both during and after the trials

Donor-advised funding can support a specific disease, geography, patient population or other theme of a donor's choosing, such as:

- Veterans
- Pediatrics
- Specific disease areas or geographies
- AI Validation
- Health equity, including women's health and health disparities

CELEBRATING 20 YEARS OF IMPACT

On October 25, 2025, we reached our 20th anniversary: 20 years of impacting patients' lives through medical repurposing. In 2005, George and Judy Goldman created the nonprofit, now known as Cures Within Reach. Because George was an entrepreneur, he wanted to start funding proof-of-concept research for people who had great ideas, but had no funds for the initial 'maybe this will work' study. 20 years later, George and Judy would be thrilled to see what Cures Within Reach has become.

*Magical Katrina
at our
"Magic of Repurposing"
event*



*Nanci Soriano
Goldman Philanthropic
Partnerships and
daughter of our
founders, George and
Judy Goldman*


Since 2005, we have funded 162 clinical trials in 94 different diseases at 102 research institutions. Our successful treatment options for patients are growing, due to publications, presentations and the follow-on clinical evidence needed for broad use by patients anywhere.

What's next? With our customizable, flexible approach, we continue to solve emerging challenges and fill gaps, from AI validation to women's health and beyond.



"This theme for this 20th anniversary celebration is ideal, since what Cures Within Reach does is absolutely magical. Our family has been collaborating with Cures Within Reach since 2018. They have built an unmatched ecosystem and process to activate researchers and turn repurposing ideas into clinical success."

Lester Knight
Chair of Roundtable Healthcare Partners



"The **University of Chicago** will always be eternally grateful to **Cures Within Reach**. Simply and profoundly, we would not have been able to support that early [focal therapy in prostate cancer] trial without the help of Cures Within Reach."

*Dr. Scott Eggener
Urology Chair, University of California, Los Angeles;
previously with University of Chicago*

NEW CLINICAL TRIALS STARTED IN 2025

16 trials at 15 institutions in 13 diseases in 6 countries

Disease Area	Institution	Title	Type	Community
Gastro-Intestinal	Kenya Medical Research Institute (KEMRI)	Repurposing Lactoferrin and Lysozyme to Address Environmental Enteric Dysfunction in Kenya	Nutraceutical, Pediatric	Health Equity, LMIC, Pediatric
Immune Disorder	University of Chicago	Non-invasive Monitoring to Detect Food Allergic Reactions	Device, Adult and Pediatric	Chicago, Health Equity, Pediatric
Infectious Disease	University of Science, Technology and Engineering of Bamako	Comparing Two Drugs to Treat P. Malariae in Mali	Drug, Adult and Pediatric	Health Equity, LMIC, Pediatric
Infectious Disease	International Centre for Diarrhoeal Disease Research, Bangladesh	Assessing a Combination Therapy for Helminthiasis in Bangladeshi Children	Drug, Pediatric	Health Equity, LMIC, Pediatric
Maternal Health	Baylor Foundation Malawi	Preventing Prematurity with Xylitol in Malawi	Nutraceutical, Adult and Pediatric	Health Equity, LMIC, Pediatric
Maternal Health <i>Selected 2025</i>	University of Lagos	Using N-Acetylcysteine to Treat Early-Onset Preeclampsia in Nigeria	Drug, Adult	Health Equity, LMIC, Pediatric
Metabolic Disorder	University of Nigeria Teaching Hospital	The Effect of Metformin on Weight Loss in Non-Diabetic, Obese Nigerians	Drug, Adult	Health Equity, LMIC
Neurology <i>Selected 2025</i>	Lagos State University	Helping Recovery After TBI with Vitamin D3 in Nigeria	Nutraceutical, Adult	Health Equity, LMIC, Neurology
Neurology	University of California, Davis	Using Fresh Frozen Plasma to Improve TBI Outcomes	Biologic, Adult	Health Equity, Neurology, Veterans
Neurology <i>Selected 2025</i>	Edward Hines Jr VA Hospital and CARES	Using a Wearable Leg Stimulation Device to Improve Mobility of Veterans with Parkinson's	Device, Adult	Chicago, Neurology, Veterans
Neurology	Providence VA Medical Center and Ocean State Research Institute	Treating PTSD with Stellate Ganglion Block via TMS Neuromodulation	Device, Adult	Neurology, Veterans
Oncology	University of Lagos	Treating High-grade Cervical Intraepithelial Neoplasia with a Skin Cancer Drug in Nigeria	Drug, Adult	Health Equity, LMIC, Oncology
Oncology <i>Selected 2025</i>	Moffitt Cancer Center	Using Empagliflozin to Treat Clonal Hematopoiesis	Drug, Adult	Oncology
Oncology <i>Selected 2025</i>	Maseno University	Improving Pre-Cancerous Lesion Treatment Among HIV-Positive Women in Kenya	Drug, Adult	Health Equity, LMIC, Oncology
Oncology, Rare <i>Selected 2025</i>	Mayo Clinic	Improving Response to CAR-T Therapy in Multiple Myeloma	Drug, Adult	Oncology, Rare
Oncology, Rare	Washington University in St. Louis	Improving Access to CAR T with Radiation in Relapsed / Refractory Multiple Myeloma	Device, Adult	Oncology, Rare

ONGOING CLINICAL TRIALS IN 2025

34 trials at 30 institutions in 28 diseases in 8 countries

Disease Area	Institution	Title	Type	Community
Dermatology	University of Antananarivo	Effect of Methotrexate as a Treatment for Moderate to Severe Atopic Dermatitis in Madagascar	Drug, Adult	Health Equity, LMIC
Ear Nose Throat	House Institute Foundation	Reducing Vertigo and Hearing Loss in Meniere's Disease by Repurposing a Common Allergy Drug	Drug, Adult	General
Ear Nose Throat	Yale University	Investigating the Effects of Blocking Immune Disease Pathways in Meniere's Disease	Drug, Preclinical	General
Ear Nose Throat	University Hospital of Munich	Treating Vestibular Neuritis Symptoms with a Thyroid Hormone	Drug, Adult	General
Ear Nose Throat	University of Illinois Chicago	Treating Chronic Sinus Inflammation with a Probiotic Sinus Wash	Drug, Adult	Chicago, Health Equity
Immune Disorder, Rare	Cincinnati Children's Hospital Medical Center	Repurposing a Rare Disease Treatment for the Immune Disorder Eosinophilic Esophagitis	Drug, Adult	Health Equity, Rare
Infectious Disease	George Washington University / Universidad El Bosque	Repurposing a Flu Treatment for Severe Dengue Patients in Colombia	Drug, Pediatric	Health Equity, LMIC, Mid-Atlantic, Pediatric
Infectious Disease	Université d'Abomey-Calavi	Adding Beta-lactam Antibiotics to Shorten Buruli Ulcer Disease Therapy in Benin	Drug, Adult and Pediatric	Health Equity, LMIC, Pediatric
Inherited Disorder, Rare	University of Chicago	Testing a Low-Dose Anti-inflammatory Tocilizumab for Acute Chest Syndrome in Sickle Cell Disease	Drug, Adult and Pediatric	Chicago, Health Equity, Pediatric, Rare
Maternal Health	Busitema University	Using Sodium Bicarbonate to Reduce Maternal / Fetal Death from Acidosis During Obstructed Labor in Uganda	Drug, Adult and Pediatric	Health Equity, LMIC, Pediatric
Neurology	Edward Hines Jr VA Hospital and CARES	Using an Approved Depression Treatment to Restore Cognitive Function in Veterans with Mild TBI and PTSD	Device, Adult	Chicago, Neurology, Veterans
Neurology	Advocate Health Care	Testing a Low-Dose of the Hypertension Drug Clonidine for PTSD in Veterans	Drug, Adult	Neurology, Veterans
Neurology	University of North Carolina at Chapel Hill	Estrogen to Prevent Chronic Pain and PTSD Following Sexual Assault	Drug, Adult	Health Equity, Neurology
Neurology	Virginia Commonwealth University	Daily Rotigotine Patch to Enhance Behavioral Therapy for Cocaine Use Disorder Recovery in Veterans	Drug, Adult	Mid-Atlantic, Neurology, Veterans
Neurology	Edward Hines Jr VA Hospital and CARES	Improving Cognitive Function in Veterans with Atypical Parkinsonism with rTMS Brain Stimulation	Device, Adult	Chicago, Neurology, Rare, Veterans
Neurology	University of Illinois Chicago	Adding an Antihistamine to Improve Outcomes in Depression	Drug, Adult	Chicago, Health Equity, Neurology
Neurology, Cardio	University of California San Francisco	Testing the Epilepsy Drug Perampanel to Prevent Seizures After Cardiac Arrest Resuscitation	Drug, Adult	Health Equity, Neurology
Neurology, Infectious Disease	Emory University School of Medicine	Addressing Chronic Pain in HIV Patients with an Approved Addiction Treatment	Drug, Adult	Health Equity, Neurology

ONGOING CLINICAL TRIALS IN 2025

34 trials at 30 institutions in 28 diseases in 8 countries

Disease Area	Institution	Title	Type	Community
Oncology	University of Illinois Chicago	Using a Generic Drug Combination in Early-Stage Hormone Receptor Positive Breast Cancer Patients	Drug, Adult	Chicago, Health Equity, Oncology
Oncology	University of Colorado, Anschutz Medical Campus	Reducing Side Effects of Breast Cancer Treatments with Oxytocin	Drug, Adult	Health Equity, Oncology
Oncology	University of Illinois Chicago	Glycyrrhizin in Prostate Cancer : A Window-of-Opportunity Clinical Trial	Nutraceutical, Adult	Chicago, Health Equity, Oncology
Oncology	University of Pittsburgh	Reducing Immune-Related Adverse Events by Adding Oral FMT to Solid Tumor Cancer Treatment	Other, Adult	Health Equity, Oncology
Oncology, Rare	Muhimbili University Health and Allied Sciences	Testing a Generic Drug Combination to Treat AML in Tanzania	Drug, Adult	Health Equity, LMIC, Oncology, Rare
Oncology, Rare	The University of Texas MD Anderson Cancer Center	Adding Metal Detoxification Drugs to Improve Childhood AML and Other Blood Cancer Outcomes	Drug, Pediatric	Oncology, Pediatric, Rare
Oncology, Rare	City of Hope	Repurposing Venetoclax and Glofitamab to Improve Patient Response in Mantle Cell Lymphoma	Drug, Adult	Health Equity, Oncology, Rare
Oncology, Rare	Colorado State University	Evaluating an Approved Drug Combination Plus Immunotherapy in Canine Metastatic Osteosarcoma	Drug, Preclinical	Oncology, Rare
Oncology, Rare	University of Michigan	Reducing CAR T-cell Therapy Complications in Relapsed Lymphoma Patients by Adding Natalizumab	Drug, Adult	Oncology, Rare
Oncology, Rare	Brigham Young University	Treating Anemia in Myelofibrosis with Nelfinavir	Drug, Adult	Oncology, Rare
Oncology, Rare	Children's Hospital of Philadelphia	Preventing Relapse After Bone Marrow Transplant in Pediatric Acute Lymphoblastic Leukemia with a Personalized Treatment	Drug, Pediatric	Mid-Atlantic, Oncology, Pediatric, Rare
Oncology, Rare	University of California, Irvine	Treating a Group of Rare Blood Cancers, Myeloproliferative Neoplasms , with N-acetylcysteine	Drug, Adult	Oncology, Rare
Oncology, Rare	Loyola University Medical Center	Repurposing the Blood Pressure Drug Minoxidil for the Treatment of Recurrent Chemo-resistant Ovarian and Other Gynecological Cancers	Drug, Adult	Chicago, Oncology, Rare
Oncology, Rare	University College Hospital Ibadan	Adding the Antibiotic Clofazimine to Chemotherapy for Triple Negative Breast Cancer in Nigeria	Drug, Adult	Health Equity, LMIC, Oncology, Rare
Rare	Children's National Research Institute	Using Steroids to Improve Outcomes in Rhabdomyolysis in Pediatric Patients	Drug, Pediatric	Health Equity, Mid-Atlantic, Pediatric, Rare
Rare, Liver Disease	Vietnam National Children's Hospital / Big Leap Research	Improving Outcomes for the Rare Liver Disease Biliary Atresia with a Cancer Drug in Vietnam	Drug, Pediatric	Health Equity, LMIC, Pediatric, Rare

CLINICAL TRIALS COMPLETED IN 2025

12 trials at 12 institutions in 12 diseases in 6 countries

Disease Area	Institution	Title	Type	Community
Ear Nose Throat	University Hospital of Munich	Identifying a Potential Biomarker and Repurposed Migraine Treatment in Meniere's Disease	Drug, Adult	General
Immune Disorder, Rare	St. Jude Children's Research Hospital	Repurposing a Blood Cancer Drug to Treat an Immune Disorder (HLH) in Children	Drug, Pediatric	Pediatric, Rare
Inflammatory Disease	SIDS Hospital and Research Centre	Combining the Cholesterol-Lowering Drug Simvastatin with N-Acetylcysteine for Chronic Pancreatitis in India	Drug, Adult	Health Equity, LMIC
Infectious Disease, Rare	International Centre for Diarrhoeal Disease Research, Bangladesh	Assessing Safety and Efficacy of Oral Ivermectin in Post Kala-azar Dermal Leishmaniasis Treatment	Drug, Adult	Health Equity, LMIC, Rare
Infectious Disease	University of Chicago	Can Vitamin D Reduce the Burden of COVID-19 in Chicago?	Nutraceutical, Adult	Chicago, Health Equity
Inherited Disorder	Global Health Uganda Ltd	Adding Zinc to Reduce Sickle Cell Anemia-related Infections in Ugandan Children	Nutraceutical, Pediatric	Health Equity, LMIC, Pediatric
Neurology	University of Zambia	Testing an Antihypertensive Drug as an Add-On Therapy for Drug-Resistant Epilepsy Patients in Zambia	Drug, Adult	Health Equity, LMIC, Neurology
Neurology	University of California, Los Angeles	Testing a Repurposed Device to Improve the Treatment of Chronic Pelvic Pain in Women	Device, Adult	Health Equity, Neurology
Oncology, Rare	University of Pittsburgh	Investigating a Rare Disease Drug to Treat AML and MDS Patients with Post-Stem Cell Transplant Relapse	Drug, Adult	Oncology, Rare
Oncology, Rare	University of Illinois Chicago	Repurposing a Diagnostic Device to Address Health Disparities in Esophageal Cancer Screening and Outcomes	Device-Diagnostic, Adult	Chicago, Health Equity, Oncology, Rare
Oncology, Rare	The University of Texas MD Anderson Cancer Center	Enhancing Treatment Response in Recurrent / Metastatic Osteosarcoma with Hydroxychloroquine	Drug, Pediatric	Health Equity, Oncology, Pediatric, Rare
Rare, Vascular	Stanford University	Treating Vascular Malformations Using the Cancer Drug Trametinib	Drug, Pediatric	Pediatric, Rare

“Thanks to the generous support of Cures Within Reach, our study advances new treatment strategies for patients with relapsed or recurrent osteosarcoma, giving patient and families renewed hope.”

Dr. Nancy Gordon

The University of Texas MD Anderson Cancer Center

CLINICAL TRIALS SELECTED IN 2025

10 trials expected to start in 2026

Disease Area	Institution	Title	Type	Community
Cardio	Translational Health Science and Technology Institute	Slowing Rheumatic Heart Disease Progression with Losartan in India	Drug, Adult	Health Equity, LMIC
Ear Nose Throat	University of California, San Francisco	Reducing Vertigo in Meniere's Disease with a CGRP Blocker	Drug, Adult	General
Ear Nose Throat	Idaho State University	Building Therapeutic Options for Meniere's Disease with Virtual Clinical Trials	Preclinical	General
Immune Disorder	Lurie Children's Hospital	Investigating Zileuton to Prevent Pediatric Food Allergy Anaphylaxis	Drug, Pediatric	Chicago, Health Equity, Pediatric
Infectious Disease	University of Nigeria	Treating Cutaneous Leishmaniasis with a Topical Antiseptic in Nigeria	Drug, Adult	Health Equity, LMIC
Maternal Health	International Centre for Diarrhoeal Disease Research, Bangladesh	Impacting Small Vulnerable Newborns with an Antimalarial Drug in Bangladesh	Drug, Adult and Pediatric	Health Equity, LMIC, Pediatric
Metabolic Disorder, Transplantation	University of Chicago	Using a Chemotherapy Drug to Reduce Post-Transplant Diabetes	Drug, Adult	Chicago
Neurology	University of Chicago	Treating PTSD in Veterans and Survivors of Violence with an ADHD Drug	Drug, Adult	Chicago, Health Equity, Veterans
Oncology	University of Chicago	Adding Lactulose to Immunotherapy to Improve Cancer Treatment Outcomes	Drug, Adult	Chicago, Oncology
Oncology	Muhimbili University	Improving Breast Cancer Surgery Outcomes with Doxycycline in Tanzania	Drug, Adult	Health Equity, LMIC, Oncology

These trials are in addition to the 6 clinical trials selected in 2025 that are already underway, listed on page 9!

“Generic repurposing is such a powerful, cost-effective approach to finding new treatments. Cures Within Reach helps Coefficient Giving find investigators and researchers that we couldn't otherwise have found.”

Coefficient
Giving

ADDING VALUE THROUGH OUR COMMUNITIES


In 2025, we continued building our nine communities and added our tenth that align with our stakeholders' strategic interests:

- **Disease-specific:** **Rare Diseases, Oncology** and **Neurology** (including neurodegenerative, mental health, pain)
- **Populations:** **Pediatrics, Veterans/Military** and **Health Equity** (impacting women's health, health disparities and underrepresented researchers)
- **Geographic:** **Chicago, Mid-Atlantic** and **Low and Lower-Middle Income Countries**
- **AI Validation:** Validating AI models' predictions of approved drug – disease matches

Most of our trials overlap communities. For example, our ongoing window-of-opportunity clinical trial in prostate cancer impacts our Chicago, Health Equity and Oncology communities.

These virtual communities engage key stakeholders with an aligned goal: bring viable treatment options to patients with unsolved diseases wherever they live.

Key Stakeholders:



"It is so great to have a partner that believes in you."

*Dr. A. Lenore Ackerman
University of California, Los Angeles*

In 2024, we announced our new AI Validation initiative and in Spring 2025, we opened the **world's first RFP to fund investigator-initiated clinical trials that clinically validate AI-generated drug–disease matches**. With our lead funding partner **Chan Zuckerberg Initiative**, and further funding from **Lyda Hill Philanthropies** and the **Searle Funds at The Chicago Community Trust**, results from these clinical trials (all with preclinical data generated by AI) will build the clinical evidence required for regulatory approval or off-label use of repurposed therapies. *Funding decisions were still pending as of the publication of this 2025 Annual Report.*


Our AI Validation efforts are designed to **activate the emerging potential of AI technologies** identifying new disease-drug repurposing combinations, **validate the clinical relevance** and **accelerate the timeline** to get these therapies into the hands of patients in need. While there may come a day when clinical trials may be conducted entirely in silico, we are not there yet. Even reaching that vision requires amassing real-world evidence that AI-generated drug-disease matches are safe and clinically relevant – which requires clinical trials in real humans.



Realizing the potential of AI models' hypotheses of approved drug – disease matches requires addressing three critical challenges:

- **Validation Gap:** validate these AI-predicted drug-disease matches in human clinical trials
- **Knowledge Bridge:** improve cross-talk between physician scientists / clinical experts and AI model developers / AI experts
- **Implementation Bottleneck:** funding and infrastructure to support the clinical trials that bring the theoretical into clinically evident

“The integration of AI into biomedical research is changing how we identify drug candidates, disease targets and therapeutic strategies. CWR’s deep engagement with patient communities and long-standing leadership in accelerating repurposed treatments will be a powerful lens through which to evaluate the promise of AI-driven predictions, particularly for rare diseases and other under-incentivized disease areas.”

**Chan
Zuckerberg
Initiative** 

This project has been made possible in part by a grant from the Chan Zuckerberg Initiative DAF, an advised fund of Silicon Valley Community Foundation and by Lyda Hill Philanthropies.

Our growing Veterans Community includes **12 clinical trials**: 7 ongoing, 4 completed (in PTSD, depression, TBI and nerve damage) plus at least 1 more starting in 2026.

We began funding 3 veterans clinical trials in 2025:

- Using Fresh Frozen Plasma to Improve **TBI** Outcomes at University of California, Davis
- Treating **PTSD** with Stellate Ganglion Block via TMS Neuromodulation at Providence VA Medical Center and Ocean State Research Institute
- Using a Wearable Leg Stimulation Device to Improve Mobility of Veterans with **Parkinson's** at Edward Hines Jr VA Hospital and CARES



Of our 50 ongoing trials at year-end, 10 are in Veterans / Military

Philanthropic Partners:



Arthur Thomas
Alm Trust



Anonymous

PEDIATRICS



*Of our 50 ongoing trials at year-end,
15 are in pediatrics or
both adult and pediatrics*

Our growing Pediatrics Community now has **28 clinical trials**: 15 ongoing, 11 completed trials plus at least 2 more starting in 2026. The 6 new pediatric trials started in 2025 include:

- Repurposing Lactoferrin and Lysozyme to Address **Environmental Enteric Dysfunction** in Kenya
- Non-invasive Monitoring to Detect **Food Allergic Reactions**
- Comparing Two Drugs to Treat **P. Malariae** in Mali
- Assessing a Combination Therapy for **Helminthiasis** in Bangladeshi Children
- Preventing **Prematurity** with Xylitol in Malawi
- Using N-Acetylcysteine to Treat Early-Onset **Preeclampsia** in Nigeria

RARE DISEASES: A PIONEER IN HOPE FOR RARE PATIENTS



While we are disease-agnostic, since our inception 20 years ago, Rare Diseases has always been and remains a clear focus of our efforts: many trials in our portfolio impact the thousands living with a rare disease without treatment options. Our fast-track approach of de-risking repurposed therapeutic options for rare diseases accelerates their availability by building the clinical data required for regulatory approval or, more frequently for rare diseases, through off-label use.

Of our 50 ongoing trials at year-end, 17 are in Rare Diseases

OUR GRANT REVIEW COMMITTEES

A Secret to our Success: Our Grant Review Committee Members

In 2025, a **record 146 volunteers**, representing research, clinicians, industry, nonprofits, philanthropy, government, AI and the patient/community voice to provide both scientific and patient perspectives, **helped us review during this record year of submissions**. We are so grateful for the time, effort and insights that these Grant Review Committee members provide. These volunteers:

- Reviewed **over 100 submissions**
- Represented **27 countries on 6 continents**
- Strengthened our selected clinical trials with their expertise and suggestions

Learn more about and join our Grant Review Committee: visit <https://bit.ly/cwrreviewers>.

“Thank you for the opportunity to serve; it was a pleasure to contribute. I appreciate the thoughtful work your team puts into advancing treatment options for patients through repurposing trials.”

*A 2025 Meniere’s Disease RFP
Grant Review Committee member*

US HEALTH EQUITY: IMPACTING HEALTH DISPARITIES OR UNDERREPRESENTED RESEARCHERS



In 2025, we continued building our portfolio in US-based health equity to positively impact health disparities and to fund underrepresented researchers. **4 new trials** in our US Health Equity portfolio started in 2025 or will start in 2026:

- Investigating Zileuton to Prevent Pediatric **Food Allergy Anaphylaxis**
- Non-invasive Monitoring to Detect **Food Allergic Reactions**
- Treating **PTSD** in Veterans and Survivors of Violence with an ADHD Drug
- Using Fresh Frozen Plasma to Improve **TBI** Outcomes


Of our 50 ongoing clinical trials at year-end, 17 are US-based Health Equity

WOMEN'S HEALTH: GROWING IMPACT IN THE US AND LMICS

The historically low funding of women's health by the NIH, industry and others has led to both significant gaps in knowledge and limited treatment options for conditions that disproportionately affect women. This is exacerbated by exclusion of women from clinical trials, often due to a pregnancy risk, and has led to a lack of data on how treatments affect women differently than men.

Our fast-growing Women's Health portfolio, within our Health Equity efforts broadly, includes clinical trials in breast cancer, ovarian cancer, pre-cervical cancers, maternal health and chronic pain.

*Of our 50 ongoing trials at year-end,
10 are in Women's Health*




LOW / LOWER-MIDDLE INCOME COUNTRIES: IMPACTING LMIC-BASED PATIENTS WITH CLINICAL TRIALS LED BY LMIC-BASED RESEARCHERS

LMIC-Based Trials

In 2025, our funding supported 9 new LMIC-based clinical trials in infectious disease, maternal health, neurology, oncology and more, plus at least 4 more will start in 2026.

Our 2025 LMIC RFP included:

- A record 80 LOIs submitted from over 18 countries
- 41 volunteer Grant Review Committee members from over 15 different countries
- Funding for community engagement alongside the trials



*Of our 50 ongoing trials at year-end,
15 are LMIC-based*

The 7 new clinical trials selected in 2025 (3 already underway) are:

- Reducing **Small Vulnerable Newborns** with an Antimalarial Drug in Bangladesh at International Centre for Diarrhoeal Disease Research, Bangladesh
- Helping Recovery After **Traumatic Brain Injury** with Vitamin D3 in Nigeria at Lagos State University College of Medicine
- Improving **Pre-Cancerous Lesion** Treatment Among HIV-Positive Women in Kenya at Maseno University
- Improving **Breast Cancer** Surgery Outcomes with Doxycycline in Tanzania at Muhimbili University of Health and Allied Sciences
- Slowing **Rheumatic Heart Disease** Progression with Losartan in India at Translational Health Science and Technology Institute
- Using N-Acetylcysteine to Treat **Early-Onset Preeclampsia** in Nigeria at University of Lagos
- Treating **Cutaneous Leishmaniasis** with a Topical Antiseptic in Nigeria at University of Nigeria

Lead Partner:

Coefficient
Giving

Since 2020, all of our clinical trials impacting US health disparities require the **engagement of community-based organizations** alongside the trials. This community engagement component, funded in partnership with **Burroughs Wellcome Fund** and others, supports the engagement of social services organizations, community health, other healthcare nonprofits and faith-based groups, and strengthens our clinical trials through better inclusion of underrepresented communities and patients throughout the entire clinical process – before the trial begins enrollment, during the trial and supporting post-trial dissemination of the results.



In 2024, we expanded this funding as an option for all our US-based clinical trials, and in 2025, we expanded once again by offering this funding for our LMIC-based clinical trials, thanks to our philanthropic partner **Coefficient Giving**. In 2026, this funding will be available for our AI Validation trials as well, thanks to our philanthropic partners **Chan Zuckerberg Initiative** and **Lyda Hill Philanthropies**.

At year-end, we had 15 ongoing trials in the US and LMICs with community engagement alongside the clinical trials.


Engaging Social Services and Faith-Based Organizations in Clinical Trials

October 16, 2025

In October 2025, we held a convening event to support clinical trial researchers and clinical trial teams, focused on the engagement of social services and faith-based organizations in clinical trials.

Moderated by Tammy Collins, PhD from Burroughs Wellcome Fund, speakers represented social services and faith-based organizations, clinical researchers and industry:

- Edilberto Amorim, MD, *University of California, San Francisco*
- Courtney Christian, MBA, MPA, *PhRMA*
- Pastor Cy Fields, *Alive Faith Network* and *New Landmark Missionary Baptist Church*
- Natalie Reizine, MD, *University of Illinois Health*
- Paris Thomas, PhD, MS, MCHES, *Equal Hope*



This session focused on the importance of valuing social services and faith-based organizations to support screening and enrollment opportunities for active clinical trials with sites nearby. Speakers discussed best practices when engaging local churches, religious charities, nonprofits, health education centers, government agencies and other community organizations trusted by patients, yet often unaware of ongoing clinical trials.

EARLY-STAGE INVESTIGATORS

For 20 years, we've been providing proof-of-concept funding for clinical repurposing trials that successfully catalyze not only new treatment options for patients, but also the careers of clinical researchers.

Early-Stage Investigators (ESIs) have completed their advanced degree or medical residency within the last ten years. The decline of medical research funding in 2025 hit ESIs hard – we cannot risk a career-changing disruption. It is critical to continue to fund ESIs, providing crucial foundational support and growing the much-needed pipeline of clinical researchers. Our past success with ESIs demonstrate our impact, and we are expanding this effort in 2026 with increased opportunities for ESIs.



“As a young researcher, I was greatly benefited by funding from Cures Within Reach. We led the first confirmatory study and subsequently the study which led to the approval of a drug for the treatment of multiple myeloma.”

*Dr. Vincent Rajkumar
Mayo Clinic*

GOLF FUNDRAISER


More than 35 golfers participated in our annual golf fundraiser held at **Rich Harvest Farms**, raising a record **\$130,000** towards our mission. A portion of the proceeds helped fund **new clinical trials impacting pediatrics and veterans.**




Special thanks to event Co-Chairs **Steve Goodfriend** and **Bobby Miller** and to our many event sponsors

BY THE NUMBERS

Clinical Trial Funding Awarded



Income By Source FY2025



BY GEOGRAPHY



as of 12.31.2025

In addition to the 34 ongoing clinical trials across the US, our ongoing trials are also in: **Bangladesh, Benin, Germany, Kenya (2), Madagascar, Malawi, Mali, Nigeria (5), Tanzania, Uganda and Vietnam**




Board of Directors

Margaret Christie, JD, *Chair*, Golan Christie Taglia LLP
Lucy Mancini-Newell, *Secretary*, Consultant
Matthew Rich, *Treasurer*, PwC
Kristina Allikmets, MD, PhD, Takeda
Steven Braun, Northwestern Mutual
Don Lo, PhD, EATRIS / REMEDI4ALL
Robert Metz, Armour Life Sciences
Nancy Sullivan, IllinoisVENTURES IIc
Eric Waehner, retired pharma industry executive



Science Advisory Board

Jeff Sherman, MD, *Chair*, Amgen (*retired*)
Andrés Klein, PhD, *Vice-Chair*, Universidad del Desarrollo
Kevin B. Clark, PhD, *Past Chair*, Consultant to NASA/NSF/others
Luis Caveda, PhD, LFB USA
Tim Cunniff, PharmD, Paragon Pharmaceuticals
Douglas Feinstein, PhD, University of Illinois Chicago
Shuli Kulak, MD, Solid Biosciences
Sandra Laney, PhD, Strategic Journey Lab
Murray Lumpkin, MD, MSc, Gates Foundation
Vidula Sukhatme, MS, GlobalCures and Emory University



Cures Within Reach

Barbara Goodman, President & CEO
Clare Thibodeaux, PhD, Vice President, Scientific Affairs
CJ Wright, PharmD, Director, Scientific Affairs
Sydney Putnam, Program Manager
plus additional part-time team members, consultants and interns



Barbara Goodman
President & CEO



Clare Thibodeaux, PhD
VP Scientific Affairs

2025 COMMUNITY MEMBERS AND PARTNERS



Becky and Lester Knight



LYDA HILL
PHILANTHROPIES

The Searle Funds
at The Chicago Community Trust



Anonymous

Arlene Alm & Arthur Thomas Alm Trust

Margaret Christie


Mari Dysart & Joel Dysart Trust

Lori and Bobby Miller

Susie and David Sherman

Walter L. Barker and Betty R. Barker Foundation

Wild Thyme Fund



- CuresWReach
- CuresWithinReach
- Cures Within Reach
- CuresWithinReach
- Cures Within Reach

Cures Within Reach

134 North LaSalle Street, Suite 1130, Chicago, Illinois 60602

(847) 745-1252 info@cureswithinreach.org